Several studies have confirmed the significant benefits of EGFR-targeted agents in several types of cancers, including NSCL, CRC, pancreatic cancer, breast cancer, and SCCHN (Table 1 and Table 2). This evidence concerns the gene EGFR and colorectal carcinoma.